Abstract: To provide a method of inducing regulatory T cells without the use of additives, disclosed herein is a method of inducing regulatory T cells comprising: a step of extracting blood from a living body; and a step of irradiating the extracted blood with ultraviolet light having a wavelength ranging between 260 nm and 320 nm. By irradiating the blood with ultraviolet light in the above specific wavelength range, it makes it possible for regulatory T cells to be induced without adding any substance to the blood extracted from a living body.

Abstract: Provided is a technique of predicting prognosis of skin cancer. A method for prognosis prediction of skin cancer includes: a step of obtaining a correlation amount correlated with an expression level of a glucose-6-phosphate dehydrogenase in a sample collected from a patient with the skin cancer; and a step of determining that the prognosis of the skin cancer is poorer when the correlation amount is large than that when the correlation amount is small.

Abstract: Provided is a technology allowing for stable supply of brain microvascular endothelium-like cells. This coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells contains at least one component of a Laminin-221 fragment or an N-terminal Vitronectin.

Abstract: The present invention provides a novel method for detecting an indicator of T cell lymphoma. The method for detecting an indicator of T cell lymphoma includes the step of detecting acetylated tubulin in a T cell that has been collected from a subject.

Abstract: Provided is a novel fluorescent probe. A compound of the following general formula (I) or a salt thereof.

Abstract: An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-? receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.

Abstract: A highly practical biomarker that is specific to esophageal cancer and minimally invasive is provided. hsa-miR-619-5p in urine, hsa-milt-1273f in urine, hsa-miR-3135b in urine, hsa-miR-4327 in urine, and hsa-miR-150-3p in urine were identified as esophageal cancer biomarkers. Esophageal cancer contraction is determined by using the expression level of these microRNAs as an index.

Abstract: An object of the present invention is to provide a marker useful for early diagnosis and differentiation of Alzheimer's disease, and use thereof. An Alzheimer's disease biomarker composed of blood flotillin is provided.

Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.

Abstract: Provided is a phototherapeutic apparatus including: a probe that is held and operated by a user and provided with a photo-irradiation unit that performs irradiation with light beams; and a body provided with a control unit that controls the light beams. The body is provided with a read unit that reads a treatment protocol registered in an IC card (mobile memory medium), and a monitor (operation indication unit) that indicates a region to be irradiated with the light beams to the user, the region being set in the treatment protocol, and the control unit causes the monitor to indicate the region to be irradiated and causes the photo-irradiation unit to perform the irradiation with the light beams at a set value set in the treatment protocol. It is possible to perform the irradiation with the light beams in accordance with the treatment protocol and safely use the phototherapeutic apparatus.

Abstract: It is a subject to provide a means of preparing highly pure vascular endothelial progenitor cells in a simple and low-cost manner. It is also a subject to provide a method for efficiently proliferating vascular endothelial progenitor cells. High-purity vascular endothelial progenitor cells are prepared by the process of differentiating pluripotent stem cells into vascular endothelial progenitor cells and purifying the vascular endothelial progenitor cells using a difference in adhesion ability between the vascular endothelial progenitor cells constituting the cell population obtained in the process and other cells. On the other hand, vascular endothelial progenitor cells are cultured and expanded in the presence of a ROCK inhibitor, a GSK-3? inhibitor, and a TGF-? receptor inhibitor in addition to basic fibroblast growth factor and epidermal growth factor.

Abstract: An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits a production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits an expression or a function of an RNA-binding protein that binds to at least one sequence selected from a hepatitis B virus RNA sequence corresponding to an enhancer I region sequence on a hepatitis B virus genome DNA or a hepatitis B virus RNA sequence corresponding to an enhancer II region sequence on the hepatitis B virus genome DNA.

Abstract: An object is to prepare an intestinal organoid having a characteristic close to the small intestine of a living body, from a pluripotent stem cell. An intestinal organoid is prepared from a pluripotent stem cell, by the following steps of: (1) differentiating the pluripotent stem cell into an endoderm-like cell; (2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell; (3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF ? receptor inhibitor, a GSK-3 ? inhibitor, and a ROCK inhibitor; (4) culturing the cell obtained in step (3) to form a spheroid; and (5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation includes culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

Abstract: An object of the present invention is to provide a sustained drug release system useful for treating eye diseases. There is provided a device for sustained release of an ophthalmic drug, comprising a drug enclosing part and an intraocular retention gas enclosing part adjacent to the drug enclosing part, the enclosing parts being provided in a hollow container having at least one opening part, wherein the drug enclosing part is isolated from the opening part by the intervention of the intraocular retention gas enclosing part.

Abstract: This invention provides an antitumor drug delivery formulation for treating a subject having a tumor more highly expressing a TUG1 gene than normal tissues or preventing the subject from tumor metastasis, comprising a polymeric micelle comprising a nucleic acid that suppresses high expression of the TUG1 gene as an active ingredient, wherein the polymeric micelle comprises a block copolymer having a cationic poly(amino acid) segment and a hydrophilic polymer chain segment and the nucleic acid, and wherein the nucleic acid is bound to a cationic group of the cationic poly(amino acid) segment to form a complex and/or the nucleic acid is incorporated in the micelle or attached into the micelle; and the polymeric micelle accumulates in the tumor.

Abstract: The present invention addresses the problem of how to provide a predictive marker useful for carcinogenesis surveillance after hepatitis C virus eradication. Provided is a predictive marker composed of a single nucleotide polymorphism specified by rs17047200. In the present invention, the single nucleotide polymorphism is detected in nucleic acid samples collected from subjects, thereby to examine the risk of developing hepatocellular carcinoma after of hepatitis C virus eradication.

Abstract: [Object] To provide a decorative aqueous composition that includes particles formed from opal-type colloidal crystals uniformly and stably dispersed in an aqueous dispersion medium, and exhibits a structural color due to interference of light, and to provide a method for producing the decorative aqueous composition. [Solution] The decorative aqueous composition of the present invention contains particles of opal-type colloidal crystals dispersed in an aqueous dispersion medium in which a polymer is dissolved. The particles of the opal-type colloidal crystals are made from hydrophilic colloidal particles having an average particle diameter ranging from 10 nm to 1000 nm with a variation coefficient of the particle diameter being within 20%. Therefore, the decorative aqueous composition of the present invention contains opal-type colloidal crystals uniformly and stably dispersed in an aqueous dispersion medium, and exhibits a structural color due to interference of light.

Abstract: An object of the present invention is to provide a new means capable of easily and efficiently preparing cells showing a function more similar to the function of intestinal epithelial cells of a living body. According to the present invention, pluripotent stem cells are induced to differentiate into intestinal stem cell-like cells by a method for inducing differentiation of pluripotent stem cells into intestinal epithelial cells, the method including a step (1) of differentiating pluripotent stem, cells into intestinal stem cell-like cells and a step (2) of differentiating the intestinal stem cell-like cells obtained in the step (1) into intestinal epithelial cell-like cells by using an MEK1 inhibitor, a DNA methylation inhibitor, a TGF? receptor inhibitor, EGF, and a cAMP activator in combination.

Abstract: Provided is an ultraviolet irradiation device capable of increasing the irradiance at an affected site (target cells) even when ultraviolet light having the same intensity is emitted. This ultraviolet irradiation device is provided with: a device body configured to be capable of emitting ultraviolet light from a light emission unit; an ultraviolet-transparent substrate disposed on the light emission unit; and an elastic member which is disposed on the surface of the substrate facing away from the device body and made of an ultraviolet-transparent material.

Abstract: An object of the present invention is to provide a photodynamic therapy light irradiation device for irradiating two kinds of light in different wavelength ranges to an irradiated surface, the device being capable of irradiating the light with uniform illuminance to the irradiated surface even having an uneven shape and obtaining a spectral distribution of high uniformity on the entire irradiated surface. A photodynamic therapy light irradiation device of the present invention is characterized by including: a light source unit having one or more LED elements that emit first light having a peak wavelength within a range of wavelengths of not shorter than 400 nm to not longer than 420 nm disposed on a flexible substrate; and a fluorescent plate configured to transmit a part of the first light from the light source unit, and to convert another part thereof into second light having a wavelength of not shorter than 500 nm to not longer than 520 nm and thereby emit the second light.